Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
April 05, 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022
April 04, 2022 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., April 04, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus
March 28, 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., March 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting
March 08, 2022 16:01 ET
|
Cara Therapeutics, Inc.
Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients Oral...
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
March 01, 2022 16:01 ET
|
Cara Therapeutics, Inc.
KORSUVA™ (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed Initiation of Oral KORSUVA (difelikefalin) Phase 3 pruritus...
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
February 25, 2022 07:15 ET
|
Cara Therapeutics, Inc.
Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefalin) as first therapy in Europe for the treatment of chronic kidney disease associated-pruritus...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
February 22, 2022 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
Cara Therapeutics to Host Virtual R&D Day on March 11, 2022
February 18, 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients
January 10, 2022 08:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...